Medicine · 2017
Pravastatin for prevention of HELLP syndrome: A case report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Otten Lucia Anna, van der Ven Katrin, Kühr Marietta, Gembruch Ulrich, Merz Waltraut Maria
Аннотация
RATIONALE: Pravastatin has emerged for prevention and treatment of preeclampsia; no reports are available on pravastatin and HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome.
PATIENT CONCERNS: The first pregnancy necessitated termination of pregnancy at gestational age (GA) 20+5 for HELLP. Intrauterine fetal death at GA 22+5 occurred in the second pregnancy, whilst on temporizing management of HELLP.
DIAGNOSES: Severe, recurrent early-onset HELLP syndrome.
INTERVENTIONS: In her fourth pregnancy, pravastatin was commenced at GA 13.
OUTCOMES: The course of pregnancy was uncomplicated, and a healthy, appropriate for gestational age fetus was delivered at term.
LESSONS: Pravastatin may be effective in prevention of HELLP. The hepatic uptake may be of particular advantage.
PATIENT CONCERNS: The first pregnancy necessitated termination of pregnancy at gestational age (GA) 20+5 for HELLP. Intrauterine fetal death at GA 22+5 occurred in the second pregnancy, whilst on temporizing management of HELLP.
DIAGNOSES: Severe, recurrent early-onset HELLP syndrome.
INTERVENTIONS: In her fourth pregnancy, pravastatin was commenced at GA 13.
OUTCOMES: The course of pregnancy was uncomplicated, and a healthy, appropriate for gestational age fetus was delivered at term.
LESSONS: Pravastatin may be effective in prevention of HELLP. The hepatic uptake may be of particular advantage.